Analysts: SanDisk Will Beat Estimates and 4 New Opinions Investors Must Take Note Of

Shoe Carnival Inc. (NASDAQ:SCVL): The company’s sales are expected by Sterne Agee to see a significant boost because of pent-up demand when the weather becomes warmer. The firm lowered its estimates, and it lowered its price target on the shares to $25 from $28 due to its belief that the company’s sales were hindered by the cold weather during Q1. The firm reiterates its Buy rating on the stock.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

SCVL

SanDisk Corp. (NASDAQ:SNDK): Nomura says it would be a buyer of Sandisk into the Q1 report due to its expectation of a beat and raise in full year revenue and margin guidance because of  pricing strength and the weak Yen. The firm gives the shares a Buy rating and a $60 price target.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

SNDK

Texas Capital BancShares Inc. (NASDAQ:TCBI): According to Stephen, the company’s EPS and investor sentiment towards the name are in the position to bottom in the near-term. The firm believes that the stock’s valuation is attractive even under a bear case scenario, and it reiterates its Overweight rating on the stock.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

TCBI

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): Leerink is convinced that the District Court of New Jersey’s judgment last night in favor of the generic challengers in the Pulmicort Respule patent dispute was not expected by investors, and it notes that Actavis (ACT) and Apotex will now have the ability to launch generic versions of Pulmicort Respule imminently because of this ruling. Leerink thinks that Pulmicort has been a significant earnings contributor for Teva, who has been paying royalties on sales of its generic version of the drug to AstraZeneca (NYSE:AZN). The firm believes that the introduction of two new generics will lower Teva’s revenue by $250 million to 300 million and earnings by 10c.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

TEVA

Tibco Software, Inc. (NASDAQ:TIBX): The company announced that its CFO would resign, causing Stifel to believes that this development is not surprising, considering Tibco’s disappointing results over the last several months. The firm continues to think that TIBCO is poised to benefit from ongoing trends, and it believes that the stock is de-risked at current levels. It reiterates its Buy rating and a $26 price target on the stock.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

TIBX

Investing Insights: Is Qualcomm A Hot Stock?

More Articles About:   , , ,  

More from The Cheat Sheet